In this study, we found that decreased miR-128-3p expression promotes CD4+ CD25+ Foxp3+ Tregs differentiation by regulating IL16 expression in GC, and this mechanisms will be a promising therapeutic target in GC immunotherapy. The gene discussed is CD4; the disease is gastric cancer.